For the year ending 2025-12-31, AMRX made $3,018,760K in revenue. $72,057K in net income. Net profit margin of 2.39%.
| Income Statement | 2025-12-31 | 2024-12-31 | ||
|---|---|---|---|---|
| Net revenue | 3,018,760 | 2,793,957 | ||
| Cost of goods sold | 1,905,452 | 1,773,519 | ||
| Gross profit | 1,113,308 | 1,020,438 | ||
| Selling, general and administrative | 526,827 | 476,436 | ||
| Research and development | 186,175 | 190,714 | ||
| In-process research and development impairment charges | 0 | - | ||
| Intellectual property legal development expenses | 7,632 | 5,845 | ||
| Change in fair value of contingent consideration | - | 930 | ||
| Restructuring and other charges | 4,208 | 2,355 | ||
| (credit) charges related to legal matters, net | 390 | -96,692 | ||
| Other operating income | 5,240 | - | ||
| Operating income | 394,096 | 249,326 | ||
| Interest expense, net | -241,091 | -258,595 | ||
| Foreign exchange gain (loss), net | 7,635 | -6,846 | ||
| Loss on refinancing | -31,365 | - | ||
| Increase in tax receivable agreement liability | -6,588 | -50,680 | ||
| Other income, net | 16,522 | 11,782 | ||
| Total other expense, net | -254,887 | -304,339 | ||
| Income (loss) before income taxes | 139,209 | -55,013 | ||
| Provision for income taxes | 11,276 | 18,863 | ||
| Net income (loss) | 127,933 | -73,876 | ||
| Less net income attributable to non-controlling interests | 55,876 | 43,010 | ||
| Net loss attributable to amneal pharmaceuticals, inc. before accretion of redeemable non-controlling interest | - | -116,886 | ||
| Net loss attributable to amneal pharmaceuticals, inc | - | -116,886 | ||
| Net income (loss) attributable to amneal pharmaceuticals, inc | 72,057 | - | ||
| Basic EPS | 0.23 | -0.38 | ||
| Diluted EPS | 0.22 | -0.38 | ||
| Basic Average Shares | 313,367,000 | 308,978,000 | ||
| Diluted Average Shares | 324,805,000 | 308,978,000 | ||
Amneal Pharmaceuticals, Inc. (AMRX)
Amneal Pharmaceuticals, Inc. (AMRX)